https://orcid.org/0000-0001-7201-9163
References
- Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, et al. Pharmacogenetics and pharmacogenomics in moderate-to-severe Psoriasis. Am J Clin Dermatol. 2018;19:209–222.
- Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules. Clin Rheumatol. 2018;37:1739–1741.
- Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, et al. Influence of genetic polymorphisms on response to biologics in moderate-to-severe Psoriasis. J Pers Med. 2021;11:293.
- Caputo V, Strafella C, Cosio T, et al. Pharmacogenomics: an update on biologics and small-molecule drugs in the treatment of Psoriasis. Genes (Basel). 2021;12:1398.
- Muñoz-Aceituno E, Martos-Cabrera L, Ovejero-Benito MC, et al. Pharmacogenetics update on biologic therapy in Psoriasis. Medicina (Kaunas). 2020;56. DOI:10.3390/medicina56120719.
- van Vugt LJ, van den Reek JMPA, Hannink G, et al. Association of HLA-C*06:02 status with differential response to ustekinumab in patients with Psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:708–715.
- Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179:1072–1080.
- Papini M, Cusano F, Romanelli M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol Eng. 2019;181:413–414.
- Cataldi C, Mari NL, Lozovoy MAB, et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm Res Off J Eur Histamine Res Soc. 2019;68:557–567.
- Bai F, Zheng W, Dong Y, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9:1266–1278.
- Khashaba SA, Attwa E, Said N, et al. Serum YKL-40 and IL 17 in Psoriasis: reliability as prognostic markers for disease severity and responsiveness to treatment. Dermatol Ther. 2021;34:e14606.
- Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9:1482.
- Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47:918–925.